Oxiglutatione

Summary

Oxiglutatione (CHEMBL1372) is an approved small molecule targeting GSR; indicated across 5 conditions including non-small cell lung carcinoma and myelodysplastic syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (GSR)
• Indications: 5 conditions
• Chemistry: 612.6 Da · C20H32N6O12S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1372
Name	Oxiglutatione
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	65359
ChEBI	CHEBI:17858
Molecular formula	C20H32N6O12S2
Molecular weight	612.6
InChIKey	YPZRWBKMTBYPTK-BJDJZHNGSA-N

SMILES: C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N

IUPAC name: (2S)-2-amino-5-[[(2R)-3-[[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

Other ChEBI roles (chemical / environmental): Escherichia coli metabolite, mouse metabolite.

Also known as: Glutathione disulfide, Oxiglutationa, Oxiglutatione, Oxiglutatione component of navstel, glutathione disulfide, SID26754399, SID29215201, Oxidised Gutathione, Glutathione Disulfide, OXIGLUTATIONE, Glutathione, Oxidized Form

Patent coverage: 3,301 distinct patent families (7,364 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GSR	glutathione-disulfide reductase	Inhibition		0.2%	P00390

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Microtubule-associated protein tau, Fructose-bisphosphate aldolase, 4’-phosphopantetheinyl transferase ffp.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
A8B2U2	5.7	Potency	1990	nM	CHEMBL_ACT_4612125

Target pathways

Aggregated over 1 target gene(s): GSR.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
Metabolism of ingested H2SeO4 and H2SeO3 into H2Se	1	GSR
Detoxification of Reactive Oxygen Species	1	GSR
Interconversion of nucleotide di- and triphosphates	1	GSR
TP53 Regulates Metabolic Genes	1	GSR
NFE2L2 regulating anti-oxidant/detoxification enzymes	1	GSR

Dominant GO biological processes

GO term	Targets
glutathione metabolic process	1
cellular response to oxidative stress	1
cell redox homeostasis	1
cellular oxidant detoxification	1

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
leukemia	2	MONDO:0005059	EFO:0000565
breast neoplasm	2	MONDO:0021100	MONDO:0007254
ovarian cancer	2	MONDO:0008170	MONDO:0008170

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

19 molecules share ≥1 primary target. Top 19 by shared-target count:

Molecule	Source	Status	Shared targets
CARMUSTINE	ChEMBL + PubChem	Phase 4 (approved)	GSR
MENADIONE	ChEMBL + PubChem	Phase 4 (approved)	GSR
METHYLENE BLUE	ChEMBL + PubChem	Phase 4 (approved)	GSR
NIFEDIPINE	ChEMBL + PubChem	Phase 4 (approved)	GSR
GLUTAMIC ACID	ChEMBL + PubChem	Phase 3 (approved)	GSR
LYSINE	ChEMBL + PubChem	Phase 2 (approved)	GSR
ELLAGIC ACID	ChEMBL	Phase 2	GSR
MOLIBRESIB	ChEMBL	Phase 2	GSR
Ceftriaxone	PubChem	Approved	GSR
Cefuroxime	PubChem	Approved	GSR
Chlorambucil	PubChem	Approved	GSR
Chlorhexidine	PubChem	Approved	GSR
Chlorpromazine	PubChem	Approved	GSR
Fluphenazine	PubChem	Approved	GSR
Ketotifen	PubChem	Approved	GSR
Meloxicam	PubChem	Approved	GSR
Promethazine	PubChem	Approved	GSR
Quercetin	PubChem	Approved	GSR
Trifluoperazine	PubChem	Approved	GSR